Pubertal development and hypogonadism in males with autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy: a retrospective study
Study context
- Population
- Males with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) fulfilling clinical criteria, Finnish APECED cohort followed up 1970–2020
- Participants
- 43 males
- Outcome
- Course of puberty and hypogonadism
Methodological detailsFollow-up to median age 42.5 years (range, 16.2-74.8)
- Follow-up to median age 42.5 years (range, 16.2-74.8)
Main finding
As reported in the abstract
- Median age at onset of spontaneous puberty, years (range)
- 13.3 (10.8-14.8)
- Testosterone used to promote puberty, patients
- 8
- Median age at start of pubertal testosterone, years (range)
- 14.9 (13.5-15.7)
- Duration of pubertal testosterone, years
- 0.7-3.3
- Median adult height, cm
- 173.0
- Difference of adult height from mid-parental target height, average SDS
- −1.3 (P < .001)
- Hypogonadism treated
- 6 patients (14%)
- Azoospermia
- 3 patients
Observational data: associations, not effects.
Original publication
Pubertal development and hypogonadism in males with autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy: a retrospective study. Eur J Endocrinol. Published 14 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →